Results 221 to 230 of about 108,133 (341)

Glucagon-like peptide-1 receptor agonists in neuropathic pain: hype or hope? [PDF]

Korean J Pain
Choi JI.
europepmc   +1 more source

Murine GLUTag Cells [PDF]

, 2015

core   +1 more source

Tirzepatide‐induced body composition changes: Implications from the SURPASS‐3 MRI substudy

Journal of Diabetes Investigation, EarlyView.
I‐Weng Yen, Hung‐Yuan Li
wiley   +1 more source

Effect of Liraglutide on Intermittent Hypoxia‐Induced Metabolic Dysfunction: From Bench to Bedside

Journal of Sleep Research, EarlyView.
ABSTRACT Intermittent hypoxia (IH)‐mediated adipose tissue inflammation with M1 macrophage polarisation plays a key role in the pathogenesis of metabolic diseases in obstructive sleep apnoea (OSA). Effective treatment strategies are so far lacking.
Cliona O'Donnell, Ailbhe King, Guillaume Vial, Emily O'Neill, Shane Crilly, Jonathan D. Dodd, David J. Murphy, Elise Belaidi, Jean‐Louis Pepin, Claire Arnaud, Donal O'Shea, Silke Ryan   +11 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes.

JAMA Netw Open
Hsiao FC, Hsu TJ, Hsieh YJ, Tung YC, Chen DY, Lin CP, Chen SW, Chu PH.   +7 more
europepmc   +1 more source

Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized placebo-controlled clinical trials. [PDF]

Ther Adv Neurol Disord
Stefanou MI, Panagiotopoulos E, Tentolouris A, Theodorou A, Papagiannopoulou G, Athanasaki A, Tsalouchidou PE, Peppa M, Lambadiari V, Konitsiotis S, Mengel A, Paraskevas GP, Tentolouris N, Tsivgoulis G.   +13 more
europepmc   +1 more source

Prevalence and Factors Associated With Symptom Profiles of Disorders of Gut‐Brain Interaction in Obesity Before and After Treatment

Neurogastroenterology &Motility, EarlyView.
DGBI symptoms are common in obesity and have the potential to exacerbate negative health outcomes. In general, the prevalence of DGBI symptoms decreases after obesity treatment, but patients can also shift from one GI symptom profile to another. ABSTRACT Background & Aims Disorders of gut‐brain interaction (DGBI) in obesity could impair health outcomes.
Esther Colomier, Janita Halminen, Malin Björck, Gudrún Höskuldsdóttir, Karin Mossberg, My Engström, Björn Eliasson, Ville Wallenius, Lars Fändriks, Jan Tack, Hans Törnblom, Magnus Simrén   +11 more
wiley   +1 more source

Unintentional periconceptional exposure to glucagon-like peptide-1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan. [PDF]

Diabetes Obes Metab
Chou YC, Weng SH, Cheng FS, Tseng CH, Hu HY, Liu CH.   +5 more
europepmc   +1 more source

Understanding Impact of Anti‐Obesity Medications on Skeletal Muscle Mass Change Is Confounded by Measurement Methods

Obesity Reviews, EarlyView.
ABSTRACT Anti‐obesity medications promote greater degrees of weight loss than lifestyle interventions alone. There is an important need to understand whether loss of skeletal muscle during pharmacologically induced weight loss is clinically significant due to its essential role in health and disease.
Arden McMath, Dympna Gallagher
wiley   +1 more source